These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 10337457)
1. Study on local inflammatory reactions and other parameters during subcutaneous mistletoe application in HIV-positive patients and HIV-negative subjects over a period of 18 weeks. Stoss M; van Wely M; Musielsky H; Gorter RW Arzneimittelforschung; 1999 Apr; 49(4):366-73. PubMed ID: 10337457 [TBL] [Abstract][Full Text] [Related]
2. Toxicity of a standardized mistletoe extract in immunocompromised and healthy individuals. van Wely M; Stoss M; Gorter RW Am J Ther; 1999 Jan; 6(1):37-43. PubMed ID: 10423645 [TBL] [Abstract][Full Text] [Related]
3. Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Gorter RW; van Wely M; Reif M; Stoss M Altern Ther Health Med; 1999 Nov; 5(6):37-44, 47-8. PubMed ID: 10550904 [TBL] [Abstract][Full Text] [Related]
4. No evidence of IFN-gamma increase in the serum of HIV-positive and healthy subjects after subcutaneous injection of a non-fermented viscum album L. extract. Stoss M; Gorter RW Nat Immun; 1998; 16(4):157-64. PubMed ID: 10366786 [TBL] [Abstract][Full Text] [Related]
5. Subcutaneous infiltrates induced by injection of mistletoe extracts (Iscador). Gorter RW; van Wely M; Stoss M; Wollina U Am J Ther; 1998 May; 5(3):181-7. PubMed ID: 10099057 [TBL] [Abstract][Full Text] [Related]
6. Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. Stein GM; Berg PA Eur J Med Res; 1999 May; 4(5):169-77. PubMed ID: 10336405 [TBL] [Abstract][Full Text] [Related]
7. Decrease of activated lymphocytes four and nine hours after a subcutaneous injection of a Viscum album L. extract in healthy volunteers. Stoss M; Peter E; Gorter RW Nat Immun; 1998; 16(5-6):185-97. PubMed ID: 11061587 [TBL] [Abstract][Full Text] [Related]
8. Immune modulation using mistletoe (Viscum album L.) extracts Iscador. Büssing A Arzneimittelforschung; 2006 Jun; 56(6A):508-15. PubMed ID: 16927532 [TBL] [Abstract][Full Text] [Related]
9. Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series. Gardin NE Phytother Res; 2009 Mar; 23(3):407-11. PubMed ID: 19003944 [TBL] [Abstract][Full Text] [Related]
10. Viscotoxin-free aqueous extracts from European mistletoe (Viscum album L.) stimulate activity of human granulocytes. Stein GM; Pfüller U; Schietzel M Anticancer Res; 1999; 19(4B):2925-8. PubMed ID: 10652574 [TBL] [Abstract][Full Text] [Related]
11. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks. Dohmen W; Breier M; Mengs U Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652 [TBL] [Abstract][Full Text] [Related]
12. [Subcutaneous manifestations of a centrocytic non-Hodgkin lymphoma at the injection site of a mistletoe preparation]. Hagenah W; Dörges I; Gafumbegete E; Wagner T Dtsch Med Wochenschr; 1998 Aug; 123(34-35):1001-4. PubMed ID: 9739765 [TBL] [Abstract][Full Text] [Related]
13. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology. Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]. Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213 [TBL] [Abstract][Full Text] [Related]
15. Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects. Huber R; Klein R; Berg PA; Lüdtke R; Werner M J Altern Complement Med; 2002 Dec; 8(6):857-66. PubMed ID: 12614536 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10. Zarković N; Kalisnik T; Loncarić I; Borović S; Mang S; Kissel D; Konitzer M; Jurin M; Grainza S Cancer Biother Radiopharm; 1998 Apr; 13(2):121-31. PubMed ID: 10850348 [TBL] [Abstract][Full Text] [Related]
17. [Mistletoe in the treatment of cancer]. Bruseth S; Enge A Tidsskr Nor Laegeforen; 1993 Mar; 113(9):1058-60. PubMed ID: 8493669 [TBL] [Abstract][Full Text] [Related]
18. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650 [TBL] [Abstract][Full Text] [Related]
19. Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy. Kirsch A; Hajto T J Altern Complement Med; 2011 Oct; 17(10):973-9. PubMed ID: 22010781 [TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of mistletoe extracts (Viscum album L.). I. Affinity chromatography of mistletoe extracts on immobilized plasma proteins. Franz H; Haustein B; Luther P; Kuropka U; Kindt A Acta Biol Med Ger; 1977; 36(1):113-7. PubMed ID: 878740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]